These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 18729845)

  • 1. A model of the long-term cost effectiveness of scheduled maintenance treatment with infliximab for moderate-to-severe ulcerative colitis.
    Tsai HH; Punekar YS; Morris J; Fortun P
    Aliment Pharmacol Ther; 2008 Nov; 28(10):1230-9. PubMed ID: 18729845
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Health-economic analysis: cost-effectiveness of scheduled maintenance treatment with infliximab for Crohn's disease--modelling outcomes in active luminal and fistulizing disease in adults.
    Lindsay J; Punekar YS; Morris J; Chung-Faye G
    Aliment Pharmacol Ther; 2008 Jul; 28(1):76-87. PubMed ID: 18410558
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A review of infliximab use in ulcerative colitis.
    Wilhelm SM; McKenney KA; Rivait KN; Kale-Pradhan PB
    Clin Ther; 2008 Feb; 30(2):223-30. PubMed ID: 18343261
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Strategies for the prevention of postoperative recurrence in Crohn's disease: results of a decision analysis.
    Ananthakrishnan AN; Hur C; Juillerat P; Korzenik JR
    Am J Gastroenterol; 2011 Nov; 106(11):2009-17. PubMed ID: 21788991
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of scheduled maintenance treatment with infliximab for pediatric Crohn's disease.
    Punekar YS; Sunderland T; Hawkins N; Lindsay J
    Value Health; 2010; 13(2):188-95. PubMed ID: 19883407
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of infliximab for the treatment of acute exacerbations of ulcerative colitis.
    Punekar YS; Hawkins N
    Eur J Health Econ; 2010 Feb; 11(1):67-76. PubMed ID: 19844750
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of 5-aminosalicylic acid therapy for maintenance of remission in ulcerative colitis.
    Yen EF; Kane SV; Ladabaum U
    Am J Gastroenterol; 2008 Dec; 103(12):3094-105. PubMed ID: 18775007
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Infliximab for the treatment of ulcerative colitis.
    Eshuis EJ; Bemelman WA; Stokkers PC
    Expert Rev Gastroenterol Hepatol; 2009 Jun; 3(3):219-29. PubMed ID: 19485804
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-per-remission analysis of infliximab compared to adalimumab among adults with moderate-to-severe ulcerative colitis.
    Lofland JH; Mallow P; Rizzo J
    J Med Econ; 2013; 16(4):461-7. PubMed ID: 23445401
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TNF-alpha gene expression in colorectal mucosa as a predictor of remission after induction therapy with infliximab in ulcerative colitis.
    Olsen T; Goll R; Cui G; Christiansen I; Florholmen J
    Cytokine; 2009 May; 46(2):222-7. PubMed ID: 19286392
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disease activity, ANCA, and IL23R genotype status determine early response to infliximab in patients with ulcerative colitis.
    Jürgens M; Laubender RP; Hartl F; Weidinger M; Seiderer J; Wagner J; Wetzke M; Beigel F; Pfennig S; Stallhofer J; Schnitzler F; Tillack C; Lohse P; Göke B; Glas J; Ochsenkühn T; Brand S
    Am J Gastroenterol; 2010 Aug; 105(8):1811-9. PubMed ID: 20197757
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness analysis of infliximab, adalimumab, golimumab and vedolizumab for moderate to severe ulcerative colitis in Spain.
    Trigo-Vicente C; Gimeno-Ballester V; Montoiro-Allué R; López-Del Val A
    Expert Rev Pharmacoecon Outcomes Res; 2018 Jun; 18(3):321-329. PubMed ID: 29192530
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Infliximab for the treatment of acute exacerbations of ulcerative colitis.
    Bryan S; Andronis L; Hyde C; Connock M; Fry-Smith A; Wang D
    Health Technol Assess; 2010 May; 14 Suppl 1():9-15. PubMed ID: 20507798
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Infliximab for the treatment of ulcerative colitis.
    Hyde C; Bryan S; Juarez-Garcia A; Andronis L; Fry-Smith A
    Health Technol Assess; 2009 Oct; 13 Suppl 3():7-11. PubMed ID: 19846023
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Optimizing effect of infliximab upon inflammatory bowel disease].
    Li SR; Sheng JQ; Li SJ; Zhao XJ
    Zhonghua Yi Xue Za Zhi; 2009 Sep; 89(36):2568-70. PubMed ID: 20137621
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-Utility Analysis of Infliximab with Standard Care versus Standard Care Alone for Induction and Maintenance Treatment of Patients with Ulcerative Colitis in Poland.
    Stawowczyk E; Kawalec P; Pilc A
    Pharmacotherapy; 2016 May; 36(5):472-81. PubMed ID: 27007213
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term effects and colectomy rates in ulcerative colitis patients treated with infliximab: a Danish single center experience.
    Teisner AS; Ainsworth MA; Brynskov J
    Scand J Gastroenterol; 2010 Dec; 45(12):1457-63. PubMed ID: 20701434
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-life treatment paradigms show infliximab is cost-effective for management of ulcerative colitis.
    Ung V; Thanh NX; Wong K; Kroeker KI; Lee T; Wang H; Ohinmaa A; Jacobs P; Fedorak RN
    Clin Gastroenterol Hepatol; 2014 Nov; 12(11):1871-8.e8. PubMed ID: 24674943
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Infliximab as a rescue therapy for hospitalized patients with severe ulcerative colitis refractory to systemic corticosteroids.
    Yamamoto-Furusho JK; Uzcanga LF
    Dig Surg; 2008; 25(5):383-6. PubMed ID: 19005257
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of persistence with infliximab on hospitalizations in ulcerative colitis.
    Carter CT; Leher H; Smith P; Smith DB; Waters HC
    Am J Manag Care; 2011 Jun; 17(6):385-92. PubMed ID: 21756009
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.